Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Thor Medical signs strategic sales agreement for Thorium-228 with global leader in targeted alpha therapy

Company: Thor Medical ASA Date: 2025-06-16 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 Thor Medical signs strategic sales agreement for Thorium-228 with global leader in targeted alpha therapy

# Thor Medical signs strategic sales agreement for Thorium-228 with global leader in targeted alpha therapy

16.6.2025 07:30:00 CEST | Thor Medical ASA | Inside information  

  

Oslo, 16 June 2025: Thor Medical ASA, a leading emerging supplier of  

alpha-emitters for next-generation precision cancer treatment, has signed a  

strategic agreement for supply of Thorium-228 to a global leader in targeted  

alpha therapy.  

  

The five-year supply agreement represents revenues of approximately NOK 200  

million (USD 20 million) for Thor Medical, with a phased ramp-up of supply in  

accordance with the planned commissioning and scaling of the company's AlphaOne  

plant, currently under construction.  

  

Thorium-228 is a precursor for Pb-212, which is widely regarded as one of the  

most promising radioisotopes for use in next-generation precision cancer  

treatments.  

  

"We are proud to supply a global frontrunner in targeted alpha therapy and to  

contribute to a broad clinical program aimed at tackling some of the most  

challenging cancers. This agreement further validates the growing momentum and  

accelerating demand for alpha-emitting radiotherapeutics and the strategic role  

Thorium-228 will play in the future of precision oncology," says Jasper C.  

Kurth, CEO of Thor Medical.  

  

The undisclosed partner is progressing an extensive portfolio of targeted alpha  

therapy programs, including advanced-stage candidates addressing a variety of  

solid tumors.  

  

AlphaOne, Thor Medical's first commercial-scale facility for high-quality  

radioisotopes entered construction in April following a final investment  

decision at the end of March. The plant will be fully operational in Q3 2026..  

  

"Global demand for alpha-emitting isotopes is outpacing available and planned  

capacity, and we are actively scaling to meet this need. Through process  

innovation and continuous debottlenecking at AlphaOne, we are positioning Thor  

Medical to reliably support the growing clinical and future commercial demand,"  

says Jasper C. Kurth, CEO of Thor Medical.  

  

The agreement represents Thor Medical's fourth commercial supply agreement,  

adding to long-term supply agreement for Thorium-228 with ARTBIO and AdvanCell,  

and a supply agreement for Pb-212 for preclinical use with a big pharma company.  

  

CONTACT  

  

Brede Ellingsæter, CFO & COO Thor Medical, +47 472 38 440,  

brede.ellingseter@thormedical.com  

  

ABOUT THOR MEDICAL ASA  

  

Thor Medical is an emerging supplier of alpha particle emitters produced from  

naturally occurring thorium. Its proprietary production process requires no  

irradiation or use of nuclear reactors, and provides reliable, environmentally  

friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical  

industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo  

Stock Exchange under the ticker symbol 'TRMED'.  

  

IMPORTANT INFORMATION  

  

This information is considered to be inside information pursuant to the EU  

Market Abuse Regulation (MAR) and is subject to the disclosure requirements  

pursuant to Section 5-12 the Norwegian Securities Trading Act. The stock  

exchange announcement was published by Brede Ellingsæter, CFOO, Thor Medical  

ASA, at the time and date stated above in this announcement.  

  

This release contains forward -looking information and statements relating to  

the business, performance, and matters that may impact the results of Thor  

Medical. Forward-looking statements are statements that are not historical facts  

and may be identified by words such as "aims," "anticipates," "believes,"  

"estimates," "expects," "foresees," "intends," "plans," "predicts," "projects,"  

"targets," "potential," and similar expressions. Such forward-looking statements  

are based on current expectations, estimates, and projections, reflect current  

views concerning future events, and are subject to risks, uncertainties, and  

assumptions, and may be subject to change without notice. Forward-looking  

statements are not guarantees of any future performance, and risks,  

uncertainties, and other important factors could cause the actual business,  

performance, results, or the industry and markets in which Thor Medical operates  

to differ materially from the statements expressed or implied in this release by  

such forward-looking statements. No representation is made that any of these  

forward-looking statements or forecasts will come to pass or that any forecasted  

performance, capacities, or results will be achieved, and you are cautioned not  

to place any undue reliance on any forward-looking statements.  

  

This release is for information purposes only and is not to be relied upon in  

substitution for the exercise of independent judgment. It is not intended as  

investment advice and under no circumstances is it to be used or considered as  

an offer to sell, or a solicitation of an offer to buy any securities or a  

recommendation to buy or sell any securities of the Company.  

  

ATTACHMENTS  

  

Download announcement as PDF.pdf -  

https://kommunikasjon.ntb.no/ir-files/17848634/18565350/6196/Download%20announce  

ment%20as%20PDF.pdf